Is an oral anticoagulant necessary for young atrial fibrillation patients with a CHA2DS2-VASc score of 1 (Men) or 2 (Women)?

Yuan Hung, Tze Fan Chao, Chia Jen Liu, Ta Chuan Tuan, Yenn Jiang Lin, Shih Lin Chang, Li Wei Lo, Yu Feng Hu, Jo Nan Liao, Fa Po Chung, Wen Yu Lin, Wei Shiang Lin, Shu Meng Cheng, Tzeng Ji Chen, Gregory Y.H. Lip, Shih Ann Chen*

*此作品的通信作者

研究成果: Article同行評審

17 引文 斯高帕斯(Scopus)

摘要

Background--Recent studies demonstrated that oral anticoagulants (OACs) should be considered for patients with atrial fibrillation and 1 risk factor in addition to sex. Because age is an important determinant of ischemic stroke, the strategy for stroke prevention may be different for these patients in different age strata. The aim of this study was to investigate whether OACs should be considered for patients aged 20 to 49 years with atrial fibrillation and a CHA2DS2-VASc score of 1 (men) or 2 (women). Methods and Results--Using the Taiwan National Health Insurance Research Database, 7374 male patients with atrial fibrillation and a CHA2DS2-VASc score of 1 and 4461 female patients with atrial fibrillation and a CHA2DS2-VASc score of 2 and all without antithrombotic therapies were identified and stratified into 3 groups by age. The threshold for the initiation of OACs for stroke prevention was set at a stroke rate of 1.7% per year for warfarin and 0.9% per year for non-vitamin K antagonist OACs. Among male patients aged 20 to 49 years with a CHA2DS2-VASc score of 1, the risk of ischemic stroke was 1.30% per year and ranged from 0.94% per year for those with hypertension to 1.71% for those with congestive heart failure. Among female patients aged 20 to 49 years with a CHA2DS2-VASc score of 2, the risk of ischemic stroke was 1.40% per year and ranged from 1.11% per year for those with hypertension to 1.67% for those with congestive heart failure. Conclusions--For atrial fibrillation patients aged 20 to 49 years with 1 risk factor in addition to sex, non-vitamin K antagonist OACs should be considered for stroke prevention to minimize the risk of a potentially fatal or disabling event.

原文English
文章編號e003839
期刊Journal of the American Heart Association
5
發行號10
DOIs
出版狀態Published - 1 10月 2016

指紋

深入研究「Is an oral anticoagulant necessary for young atrial fibrillation patients with a CHA2DS2-VASc score of 1 (Men) or 2 (Women)?」主題。共同形成了獨特的指紋。

引用此